Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex
Amgen Inc. and Novartis AG are busy shoring up the case for their CGRP inhibitor erenumab – which is in a race with three others to be the first on to the migraine market. Positive topline Phase II data with erenumab has been reported but analysts suggest they may not be as strong as those from its competitors. The four CGRP inhibitors are all in Phase III with late-stage data expected this year.
Register for our free email digests: